Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5460 in its research report dated January 25, 2023.

Dr Reddy’s Laboratories reported a 77 percent growth in consolidated net profit at Rs 1,247 crore for the quarter ended December 31, 2022 as against Rs 707 crore a year ago. On a sequential basis, the profit grew 12 percent.

Following completion of the full set of clinical studies, Dr Reddy's said it will now prepare to file in the US, European Union and other regions for approval of 'DRL_RI'.

The company will collaborate with partner Fresenius Kabi to commercialise the proposed biosimilar for treating illnesses such as arthritis and non-Hodgkin's lymphoma in the US but plans to take the product directly to EU and other regions

The drug will be retailed in the Indian market at an 85 percent reduction from the current MRP to increase affordability and access, the pharma company has said

In a regulatory filing, the company said on December 22, 2022 and December 27, 2022, the plaintiffs voluntarily dismissed Dr Reddy's Laboratories Ltd and Dr Reddy's Laboratories, Inc. respectively, from the case.

Revlimid, also known as lenalidomide, is an oral drug that is used for the treatment of multiple myeloma or blood cancer

Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5460 in its research report dated December 21, 2022.

Nifty after peaking out near 18887 levels, witnessed some profit booking, led by the major frontline IT stocks witnessing some profit booking and shedding their gains from their peak levels, accompanied by the Metal sector also lost some momentum.

Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 5180 in its research report dated October 29, 2022.

ICICI Direct is bullish on Dr Reddy's Laboratories recommended buy rating on the stock with a target price of Rs 5215 in its research report dated October 29, 2022.

Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated October 31, 2022.

Sales from the North American market, nearly 50 percent of overall sales, grew 48 percent at Rs 2,800 crore for September quarter

Dr Reddy's Q2 result: The drugmaker reported a 9% YoY increase in consolidated revenues at Rs 6,305 crore for the reported quarter

Dr Reddy’s North American operations will set the tone for the September quarter performance, as likely price erosion will trigger a decline in sales on a year-on-year basis